financetom
Business
financetom
/
Business
/
Pillsbury Maker General Mills Annual Profit Outlook Disappoints, Stock Falls
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Pillsbury Maker General Mills Annual Profit Outlook Disappoints, Stock Falls
Jun 26, 2024 6:26 AM

General Mills, Inc ( GIS ) shares are trading lower after the company reported worse-than-expected fourth quarter FY24 revenue.

The company reported a fourth quarter sales decline of 6.3% year-on-year to $4.71 billion, missing the analyst consensus estimate of $4.85 billion.

The revenue decrease reflected unfavorable net price realization and mix and lower pound volume.

Organic net sales decreased 6% and slowed from the third-quarter trend.

North American retail segment sales declined 7% to $2.85 billion, pet segment sales declined 8% to $602 million, and International segment sales fell 10% to $668 million.

Adjusted EPS of $1.01 beat the consensus estimate of $0.99.

Gross margin expanded 140 basis points Y/Y to 35.8%. Adjusted gross margin slipped ten basis points to 34.9%.

Operating margin expanded 20 basis points to 16.5%, and operating income decreased 5% to $779 million.

General Mills ( GIS ) held $418 million in cash and equivalents as of May 26, 2024. Operating cash flow for twelve months totaled $3.3 billion.

General Mills ( GIS ) repurchased about 29 million shares of common stock in fiscal 2024 for a total of $2 billion.

The board of directors declared a quarterly dividend of $0.60 per share, payable August 1, 2024, to shareholders of record July 10, 2024, representing a 2 percent increase from the previous quarterly rate of $0.59 per share. 

"We delivered on our updated guidance in fiscal 2024 by pivoting our plans and enhancing our efficiency in response to a more challenging operating environment," said Chairman and CEO Jeff Harmening.

Outlook: General Mills ( GIS ) sees FY25 organic sales growth of 0 to +1%. The company sees FY25 adjusted EPS of (1)% to +1% in constant currency from the base of $4.52 earned in FY24. The consensus estimate is $4.68.

Price Action: At the last check on Wednesday, GIS shares were trading lower by 4.97% at $63.92 in the premarket.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Riot Platforms proposes to buy crypto miner Bitfarms, becomes largest shareholder
Riot Platforms proposes to buy crypto miner Bitfarms, becomes largest shareholder
May 28, 2024
May 28 (Reuters) - Riot Platforms ( RIOT ) said on Tuesday it has offered to acquire all outstanding shares of Bitfarms ( BITF ) for about $950 million in total equity value, even after a private proposal was rejected by the crypto miner's board last month. We were disappointed to learn that the Bitfarms Board rejected our compelling proposal...
US Supreme Court rebuffs lawyer Michael Avenatti's bid to overturn Nike-related convictions
US Supreme Court rebuffs lawyer Michael Avenatti's bid to overturn Nike-related convictions
May 28, 2024
WASHINGTON, May 28 (Reuters) - The U.S. Supreme Court declined on Tuesday to hear a bid by imprisoned celebrity lawyer Michael Avenatti to overturn his conviction for defrauding a client and extorting athletic wear company Nike ( NKE ). The justices turned away Avenatti's appeal after a lower court upheld his 2020 convictions. In another trial, Avenatti in 2022 was...
Why Mid-Cap Corcept Therapeutics Stock Trading Higher On Tuesday?
Why Mid-Cap Corcept Therapeutics Stock Trading Higher On Tuesday?
May 28, 2024
Tuesday, Corcept Therapeutics Incorporated ( CORT ) announced that the GRACE Phase 3 trial of relacorilant in patients with hypercortisolism (Cushing’s syndrome) met its primary endpoint. In April, Corcept announced that patients in GRACE’s initial, open-label phase exhibited clinically meaningful and statistically significant improvements in hypertension, hyperglycemia, and other symptoms experienced by patients with Cushing’s syndrome.  Related: Mid-Cap Corcept Therapeutics Reveals Data From Hormonal Disorder Study,...
Elanco Says FDA Confirms Bovaer Meets Safety, Efficacy Requirements
Elanco Says FDA Confirms Bovaer Meets Safety, Efficacy Requirements
May 28, 2024
09:34 AM EDT, 05/28/2024 (MT Newswires) -- Elanco Animal Health ( ELAN ) said Tuesday the US Food and Drug Administration has completed a review of methane-reducing feed ingredient Bovaer and concluded that it meets safety and efficacy requirements for use in lactating dairy cattle. Elanco said it expects product launch starting in Q3. The company and Dsm-firmenich have signed...
Copyright 2023-2025 - www.financetom.com All Rights Reserved